Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1241

RG7716-ANG2-hIgG1

Home » Antibodies » RG7716-ANG2-hIgG1

Background of RG7716-ANG2-hIgG1

RG7716 (also known as Faricimab) was an investigational drug developed by Genentech, a subsidiary of Roche. RG7716 is a novel bispecific antibody designed to target two key proteins involved in various eye diseases, particularly retinal diseases like neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). RG7716-ANG2-hIgG1 is is a monoclonal antibody specifically designed to target ANG2 in order to provide targeted therapy.

Specifications

Catalog Number:
KB-1241
Antibody Name:
RG7716-ANG2-hIgG1
Isotype:
Human IgG1,lambda
FC Muations:
Target:
ANG2
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Anti-VEGF/anti-angiopoietin-2 bispecific antibody RG7716 in diabetic macular edema: complete 36-week results from the phase 2, multicenter, randomized, active treatment-controlled BOULEVARD clinical trial